Corbus Pharmaceuticals Holdings, Inc. - 10-Q Filing

Corbus Pharmaceuticals reports Q3 2025 financial results including research and development expense trends and updated equity compensation activity.

SEC EDGAR ·

Tickers: $CRBP

Read the full article at SEC EDGAR

More Regulatory news